Treatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study

ArticleAçık Erişim

Özet

Objective: Delayed admission of myocardial infarction (MI) patients is an important prognostic factor. In the present nationwide registry (TURKMI-2), we evaluated the treatment delays and outcomes of patients with acute MI during the Covid-19 pandemic and compaired with a recent pre-pandemic registry (TURKMI-1). Methods: The pandemic and pre-pandemic studies were conducted prospectively as 15-day snapshot registries in the same 48 centers. The inclusion criteria for both registries were aged ≥18 years and a final diagnosis of acute MI (AMI) with positive troponin levels. The only difference between the 2 registries was that the pre-pandemic (TURKMI-1) registry (n=1872) included only patients presenting within the first 48 hours after symptom-onset. TURKMI-2 enrolled all consecutive patients (n=1113) presenting with AMI during the pandemic period. Results: A comparison of the patients with acute MI presenting within the 48-hour of symptom-onset in the pre-pandemic and pandemic registries revealed an overall 47.1% decrease in acute MI admissions during the pandemic. Median time from symptom-onset to hospital-arrival increased from 150 min to 185 min in patients with ST elevation MI (STEMI) and 295 min to 419 min in patients presenting with non-STEMI (NSTEMI) (p-values <0.001). Door-to-balloon time was similar in the two periods (37 vs. 40 min, p=0.448). In the pandemic period, percutaneous coronary intervention (PCI) decreased, especially in the NSTEMI group (60.3% vs. 47.4% in NSTEMI, p<0.001; 94.8% vs. 91.1% in STEMI, p=0.013) but the decrease was not significant in STEMI patients admitted within 12 hours of symptom-onset (94.9% vs. 92.1%; p=0.075). In-hospital major adverse cardiac events (MACE) were significantly increased during the pandemic period [4.8% vs. 8.9%; p<0.001; age- and sex-adjusted Odds ratio (95% CI) 1.96 (1.20-3.22) for NSTEMI, p=0.007; and 2.08 (1.38-3.13) for STEMI, p<0.001]. Conclusion: The present comparison of 2 nationwide registries showed a significant delay in treatment of patients presenting with acute MI during the COVID-19 pandemic. Although PCI was performed in a timely fashion, an increase in treatment delay might be responsible for the increased risk of MACE. Public education and establishing COVID-free hospitals are necessary to overcome patients' fear of using healthcare services and mitigate the potential complications of AMI during the pandemic. © 2020 by Turkish Society of Cardiology.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13271Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorErol, Mustafa Kemal
dc.contributor.authorKayıkçıoğlu, Meral
dc.contributor.authorKılıçkap, Mustafa
dc.contributor.authorGüler, Arda
dc.contributor.authorYıldırım, Abdullah
dc.contributor.authorKahraman, Fatih
dc.contributor.authorCan, Veysi
dc.contributor.authorİnci, Sinan
dc.contributor.authorBaysal, Sadettin Selçuk
dc.contributor.authorEr, Okan
dc.contributor.authorZeybey, Utku
dc.contributor.authorKafkas, Çağrı
dc.contributor.authorYayla, Çağrı
dc.contributor.authorArın, Can Baba
dc.contributor.authorAktaş, İbrahim
dc.contributor.authorYalçın, Ahmet Arif
dc.contributor.authorGenç, Ömer
dc.contributor.authorCosgun, Mehmet
dc.contributor.authorInanir, Mehmet
dc.contributor.authorYalçin, Osman Yasin
dc.contributor.authorGunes, Yilmaz
dc.contributor.authorKurt, Ibrahim Halil
dc.contributor.authorAsoglu, Ramazan
dc.contributor.authorErdol, Mehmet Akif
dc.contributor.authorCetin, Mustafa
dc.contributor.authorErtem, Ahmet Goktuğ
dc.contributor.authorOrnek, Ender
dc.contributor.authorYılmaz Oztekin, Gulsum Meral
dc.contributor.authorGenc, Ahmet
dc.contributor.authorGitmez, Mesut
dc.contributor.authorAksuyek, Soner
dc.contributor.authorAri, Hasan
dc.contributor.authorGazi, Emine
dc.contributor.authorAkray, Anil
dc.contributor.authorDeveci, Onur Sinan
dc.contributor.authorOzturk, Onder
dc.contributor.authorCandemir, Aytac
dc.contributor.authorYavuzgil, Oguz
dc.contributor.authorBakirci, Eftal Murat
dc.contributor.authorDegirmenci, Husnu
dc.contributor.authorFedai, Halil
dc.contributor.authorBesli, Feyzullah
dc.contributor.authorInce, Orhan
dc.contributor.authorHancıoglu, Emirhan
dc.contributor.authorOflar, Ersan
dc.contributor.authorAkurk, Ibrahim Faruk
dc.contributor.authorÇaglar, Nihan Turhan
dc.contributor.authorAylin Yamac Halac, İlke Celikkale Hatice
dc.contributor.authorKalyoncuoglu, Muhsin
dc.contributor.authorCeneli, Dogancan
dc.date.accessioned2026-10-18T20:28:06.579792835Z
dc.date.available2026-10-18T20:28:06.579792835Z
dc.date.issued2020
dc.description.abstractObjective: Delayed admission of myocardial infarction (MI) patients is an important prognostic factor. In the present nationwide registry (TURKMI-2), we evaluated the treatment delays and outcomes of patients with acute MI during the Covid-19 pandemic and compaired with a recent pre-pandemic registry (TURKMI-1). Methods: The pandemic and pre-pandemic studies were conducted prospectively as 15-day snapshot registries in the same 48 centers. The inclusion criteria for both registries were aged ≥18 years and a final diagnosis of acute MI (AMI) with positive troponin levels. The only difference between the 2 registries was that the pre-pandemic (TURKMI-1) registry (n=1872) included only patients presenting within the first 48 hours after symptom-onset. TURKMI-2 enrolled all consecutive patients (n=1113) presenting with AMI during the pandemic period. Results: A comparison of the patients with acute MI presenting within the 48-hour of symptom-onset in the pre-pandemic and pandemic registries revealed an overall 47.1% decrease in acute MI admissions during the pandemic. Median time from symptom-onset to hospital-arrival increased from 150 min to 185 min in patients with ST elevation MI (STEMI) and 295 min to 419 min in patients presenting with non-STEMI (NSTEMI) (p-values <0.001). Door-to-balloon time was similar in the two periods (37 vs. 40 min, p=0.448). In the pandemic period, percutaneous coronary intervention (PCI) decreased, especially in the NSTEMI group (60.3% vs. 47.4% in NSTEMI, p<0.001; 94.8% vs. 91.1% in STEMI, p=0.013) but the decrease was not significant in STEMI patients admitted within 12 hours of symptom-onset (94.9% vs. 92.1%; p=0.075). In-hospital major adverse cardiac events (MACE) were significantly increased during the pandemic period [4.8% vs. 8.9%; p<0.001; age- and sex-adjusted Odds ratio (95% CI) 1.96 (1.20-3.22) for NSTEMI, p=0.007; and 2.08 (1.38-3.13) for STEMI, p<0.001]. Conclusion: The present comparison of 2 nationwide registries showed a significant delay in treatment of patients presenting with acute MI during the COVID-19 pandemic. Although PCI was performed in a timely fashion, an increase in treatment delay might be responsible for the increased risk of MACE. Public education and establishing COVID-free hospitals are necessary to overcome patients' fear of using healthcare services and mitigate the potential complications of AMI during the pandemic. © 2020 by Turkish Society of Cardiology.
dc.description.sponsorshipFunding text 1: Statistical analyses were conducted by Omega CRO, Ankara, Turkey. The same electronic case report forms and data capture program were used for both registries (OpenClinica LLC and collaborators, Waltham, MA, USA, hosted by Omega CRO, Ankara, Turkey). Both TURKMI registries are investigator-initiated trials sponsored by the Turkish Society of Cardiology, which receives major unrestricted funding from Astra-Zeneca Company for this project. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.; Funding text 2: Acknowledgments: Statistical analyses were conducted by Omega CRO, Ankara, Turkey. The same electronic case report forms and data capture program were used for both registries (OpenClinica LLC and collaborators, Waltham, MA, USA, hosted by Omega CRO, Ankara, Turkey). Both TURKMI registries are investigator-initiated trials sponsored by the Turkish Society of Cardiology, which receives major unrestricted funding from Astra-Zeneca Company for this project. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
dc.identifier.doi10.14744/anatoljcardiol.2020.98607
dc.identifier.issn2149-2263
dc.identifier.issue5
dc.identifier.pmid33122486
dc.identifier.scopus2-s2.0-85094935438
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13271
dc.identifier.volume24
dc.language.isoen
dc.publisherTurkish Society of Cardiology
dc.relation.ispartofAnatolian Journal of Cardiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute myocardial infarction
dc.subjectCOVID-19
dc.subjectPandemic
dc.subjectTotal ischemic time
dc.subjectTreatment delay
dc.subjectAged
dc.subjectCoronary Angiography
dc.subjectCoronavirus Infections
dc.subjectEmergency Medical Services
dc.subjectFemale
dc.subjectHeart Failure
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Infarction
dc.subjectPandemics
dc.subjectPercutaneous Coronary Intervention
dc.subjectPneumonia, Viral
dc.subjectPrognosis
dc.subjectRegistries
dc.subjectRegression Analysis
dc.subjectShock, Cardiogenic
dc.subjectST Elevation Myocardial Infarction
dc.subjectTime Factors
dc.subjectTime-to-Treatment
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjecttroponin
dc.subjectacute heart infarction
dc.subjectadult
dc.titleTreatment delays and in-hospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus75
rdl.oa.statusgold
rdl.source.indexSCOPUS